Target Information

PERCEPTEC GmbH, founded in May 2024 in Jena, is an innovative MedTech startup focused on advancing digitization and automation within the optical and ophthalmology sectors. The company is centered around the revolutionary redesign of a virtual vision test that combines an intuitive testing process with advanced 3D display technology, aiming to enhance the efficiency and accessibility of eye diagnostics globally. According to the World Health Organization, only 36% of the 2.2 billion visually impaired individuals worldwide have sufficient access to appropriate diagnostics and care, highlighting a significant medical supply deficit with extensive societal implications.

The conventional vision test has seen little innovation in over a century, remaining stationary, space-consuming, time-intensive, and reliant on equipment and personnel. PERCEPTEC addresses these challenges through the internal development of an automated, user-friendly testing procedure, visualized with cutting-edge 3D display technology from partnerships. This enables a virtual vision test that can be performed quickly, independently, and in a space-efficient manner, resulting in cost-effective determinations of visual impairments while optimizing the diagnostic process for users. This initiative aims to create accessible and widespread access to precise diagnostics.

Industry Overview in Germany

The healthcare and MedTech sectors in Germany exhibit significant growth potential, driven by increasing demand for innovative solutions in diagnostics and patient care. With the aging population and rising prevalence of eye-related health issues, there is a pressing need for advanced technologies that streamline diagnostic processes and improve patient access to healthcare services.

Germany ranks as one of the leading healthcare markets in Europe, characterized by a strong focus on research and development, as well as a favorable regulatory environment for MedTech innovations. The integration of digital solutions within traditional healthcare settings is expected to facilitate improved patient outcomes while reducing overall costs. The rising significance of telemedicine further accentuates the need for innovative diagnostic tools such as those developed by PERCEPTEC.

In the context of PERCEPTEC, the initial target market comprises stationary optometrists and ophthalmologists in the DACH region (Germany, Austria, Switzerland) and its neighboring countries. The potential replacement market for vision testing devices is estimated at approximately 85,000 units. The high willingness of users to invest, paired with unique product features, is anticipated to drive rapid market penetration. Following initial establishment in DACH, PERCEPTEC plans to expand into additional European and international markets.

Furthermore, the automated vision test can also be utilized in patient-facing facilities, such as primary care practices, health centers, or pharmacies. After successfully entering the stationary market, mobile applications are envisaged, targeting screenings in schools or rural areas with limited ophthalmological care.

The Rationale Behind the Deal

The joint seed investment from bm|t and Sparkasse Jena-Saale-Holzland lays the foundation for targeted and sustainable progress for PERCEPTEC GmbH. The capital raised is intended for further development, clinical validation, and certification of the software-based testing procedure, with the goal of launching a medical product in 2027 and subsequently expanding the product portfolio. A second closing of the seed round remains open until September 2025, with additional private investors sought to maximize funding through various grants.

Investor Information

bm|t, based in Erfurt, is a leading investment management firm for corporate participations in Thuringia. The firm currently manages twelve funds with a total volume of approximately €445 million, investing in innovative companies across nearly all industries and development stages—spanning from startups to growth phases and corporate successors.

Sparkasse Jena-Saale-Holzland has been rooted in the region since 1828, offering financial services, consulting, and funding for businesses and communities. As the largest regional financial partner, they are committed to enhancing quality of life through digitalization, financing, and public programs, while actively supporting the economy, education, sports, and culture within the region. Their collaboration with startup platforms aims to strengthen the regional startup ecosystem.

View of Dealert

From an investment perspective, the deal between bm|t, Sparkasse Jena-Saale-Holzland, and PERCEPTEC appears promising. The focus on a highly innovative and disruptive product in the medical diagnostics field presents a substantial growth opportunity, especially in light of the identified market need for enhanced accessibility to visual diagnostics.

The projected expansion plans into additional markets, combined with the existing demand for effective vision testing solutions, bolster the potential for investors to see favorable returns. Additionally, the provision of funding through grants and incentives serves to leverage investment while reducing risk exposure.

Moreover, PERCEPTEC's innovative approach to the conventional vision test could position it as a market leader in the shift towards digitization within the healthcare sector. This aligns with broader trends favoring technology-driven solutions in diagnostics, a sector ripe for disruption.

However, the company must navigate challenges related to regulatory approvals, market acceptance of new technology, and ensuring consistent quality and reliability of their product. With a solid investment foundation and a clear growth strategy, PERCEPTEC is well-positioned to meet these challenges head-on, making it an attractive investment opportunity in the evolving MedTech landscape.

View Original Article